Last reviewed · How we verify
Mid Metformin
At a glance
| Generic name | Mid Metformin |
|---|---|
| Also known as | Metformin, Leucine, L-Leucine, Metformin, Leucine, L-Leucine |
| Sponsor | NuSirt Biopharma |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Comparative Evaluation of Topical 30% Metformin and Kligman's Regimen in Women With Melasma (NA)
- Focusing on the Menopausal Transition to Improve Mid-Life Women's Health (PHASE2, PHASE3)
- Community-based, eHealth Supported Type 2 Diabetes Care by Lay Village Health Workers in Rural Lesotho (NA)
- Pilot Study on Evaluating the Geroprotective Effect of Metformin (PHASE2)
- A Study to Access the Efficacy in Type 2 Diabetes Mellitus on Stable Metformin (PHASE1, PHASE2)
- A Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes (PHASE2)
- CS02 vs Placebo With Metformin in Type 2 Diabetes Mellitus (T2DM) (PHASE2)
- Dose Comparisons of Leucine-Metformin Combinations on Blood Glucose Levels In Type 2 Diabetic Patients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mid Metformin CI brief — competitive landscape report
- Mid Metformin updates RSS · CI watch RSS
- NuSirt Biopharma portfolio CI